Domestic pharmaceutical players have sought government intervention to resolve the trade margin issue with distributors who are refusing to stock essential medicines of specific companies till their demands of higher commissions are met.
While companies such as Abbott and Sun Pharma, who have not yet agreed to raise trade margins, are facing a boycott of their price-controlled drugs by stockists, others like Cipla, Torrent, Mankind and Lupin have succumbed under pressure and eased margins for retailers and distributors to ensure continued availability of their drugs.
A new drug pricing policy, implemented earlier this year, imposed caps on prices of 348 essential medicines (the average of the prices of brands with at least 1% share in a category as existed in may 2012 with provision of inflation-linked adjustments) and recommended margins for wholesalers and retailers from 10% and 20% on the maximum retail price earlier to 8% and 16% on the price to the retailer.
The wholesalers and retailers want these margins to be maintained at the earlier levels, forcing many companies to give the trade slightly higher margins than prescribed under the new DPCO, while compressing their own margins as the final price to the consumer is capped.
This has led to a situation where the trading community refuses to lift stocks (of both price controlled and control-free medicines) from companies that donít provide them the higher margins demanded.
An industry insider said Zydus Cadila and Aristo Pharma were the latest companies who have ďagreed to hike margins for essential drugs till a final decision is takenĒ. The move could impact their margins.
According to Edelweiss Securities, the revenue loss to the pharma companies ó on account of price control ó can be anywhere between 10% and 24% if the prescribed margins are paid and applied on the retail price. Price-controlled drugs account for around 15% of the R79,000-crore domestic pharma market.
ďThe industry has suffered a loss of R2,000 crore on account of deep price cuts of essential medicines. It is, therefore, unable to absorb additional loss of some R750 crore on the account of higher